Wegovy: The Leading FDA-Approved Weight Loss Injection
How it Works
Wegovy contains semaglutide at a higher dose than Ozempic (up to 2.4 mg vs 2 mg weekly). It activates GLP-1 receptors to reduce appetite, slow gastric emptying, and increase satiety. Acting on hypothalamic appetite centers, it reduces food cravings and overall caloric intake. The higher dose formulation was specifically optimized for maximum weight-loss efficacy in individuals with obesity or overweight.
Dosing Schedule
Weight Loss Data
Adults with obesity (without diabetes) lost 14.9% of body weight vs 2.4% with placebo. 86.4% achieved at least 5% weight loss; 32.0% achieved at least 20%.
Combined with intensive behavioral therapy (30 counseling sessions), participants achieved 16.0% weight loss vs 5.7% with placebo plus behavioral therapy.
Over 2 years, Wegovy maintained 15.2% weight loss vs 2.6% with placebo, demonstrating durable long-term efficacy without significant weight regain during continued treatment.
In adolescents aged 12-17 with obesity, semaglutide 2.4 mg reduced BMI by 16.1% vs a 0.6% increase with placebo.
In 17,604 adults with overweight/obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg reduced MACE by 20% (HR 0.80, 95% CI 0.72-0.90). This led to a new FDA indication for cardiovascular risk reduction.
Side Effects
Common / Manageable
- Nausea (reported in 44% of patients at 2.4 mg)
- Diarrhea (reported in 30%)
- Vomiting (reported in 24%)
- Constipation (reported in 24%)
- Abdominal pain (reported in 20%)
- Headache
- Fatigue
- Dyspepsia
- Dizziness
- Abdominal distension
Serious / Rare
- Pancreatitis (acute)
- Thyroid C-cell tumors (boxed warning)
- Gallbladder disease (reported in 2.6% vs 1.2% placebo in STEP 1)
- Acute kidney injury
- Hypoglycemia
- Suicidal behavior and ideation (under FDA review)
- Serious allergic reactions
- Increased heart rate (mean increase of 1-4 bpm)
Cost
What Is Wegovy?
Wegovy (semaglutide 2.4 mg) is an FDA-approved once-weekly injectable medication for chronic weight management. It was approved in June 2021 and is manufactured by Novo Nordisk. Wegovy contains the same active ingredient as Ozempic (semaglutide) but at a higher dose specifically optimized for weight loss. It is intended for long-term use alongside a reduced-calorie diet and increased physical activity in adults with obesity (BMI >= 30) or overweight (BMI >= 27) with at least one weight-related condition. In March 2024, Wegovy received an additional indication for reducing cardiovascular risk based on the SELECT trial.
The SELECT Cardiovascular Trial: A Landmark Finding
The SELECT trial was a game-changing study that enrolled 17,604 adults aged 45 and older with established cardiovascular disease and a BMI of 27 or greater, but without diabetes. Participants were randomized to semaglutide 2.4 mg or placebo and followed for a mean of 39.8 months. The results showed a 20% reduction in the composite endpoint of cardiovascular death, non-fatal heart attack, and non-fatal stroke (HR 0.80). This was the first time a weight-management medication demonstrated cardiovascular benefit independent of diabetes, fundamentally shifting how obesity is viewed as a cardiovascular risk factor. The trial led the FDA to grant Wegovy a cardiovascular risk reduction indication in March 2024.
Weight Loss Results from STEP Trials
Wegovy's efficacy was established through the STEP clinical trial program. The results were consistent across populations: patients without diabetes lost approximately 15% of body weight, those with diabetes lost 7-10%, and adolescents saw significant BMI reductions. What distinguished the STEP program from earlier obesity drug trials was both the magnitude of weight loss and the proportion of patients who achieved clinically meaningful thresholds. In STEP 1, nearly 1 in 3 patients lost 20% or more of their body weight, approaching outcomes previously seen only with bariatric surgery. The STEP 5 two-year data confirmed that weight loss is maintained with ongoing treatment.
Wegovy Dosing and What to Expect
Wegovy uses a 16-week dose escalation to reach the 2.4 mg maintenance dose. Each dose level is maintained for 4 weeks before increasing. This gradual approach is designed to reduce gastrointestinal side effects, which are most common during escalation. Wegovy comes in single-dose, pre-filled pens for each dose level (0.25, 0.5, 1.0, 1.7, and 2.4 mg). Patients should expect the most GI discomfort during the first 1-2 weeks at each new dose, with symptoms typically improving by week 3-4. Weight loss generally becomes noticeable during the 0.5-1.0 mg phase and accelerates as the dose increases.
Access, Cost, and the Coverage Challenge
Wegovy has one of the highest list prices among GLP-1 medications at approximately $1,349 per month. Insurance coverage is the primary barrier to access: many commercial plans exclude anti-obesity medications, and Medicare Part D has historically been prohibited from covering them (though this is evolving with legislative efforts). Novo Nordisk offers a savings card that can reduce commercial copays for eligible patients. Some employer-sponsored plans have begun covering Wegovy, particularly after the SELECT cardiovascular data demonstrated medical necessity beyond cosmetic weight loss. Patients should appeal coverage denials using the SELECT trial data and cardiovascular risk reduction indication as evidence of medical necessity.
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. Individual results may vary.
Frequently Asked Questions
Wegovy and Ozempic both contain semaglutide and are made by Novo Nordisk. The key differences are the approved indication (Wegovy for weight management, Ozempic for type 2 diabetes), maximum dose (2.4 mg vs 2 mg), and pen presentation (Wegovy uses single-dose pens while Ozempic uses multi-dose pens). Wegovy also has a cardiovascular risk reduction indication for overweight/obese patients without diabetes, which Ozempic does not.
Coverage varies significantly. Many commercial insurance plans now cover Wegovy, especially after the SELECT cardiovascular data, but it often requires prior authorization demonstrating a qualifying BMI and at least one weight-related comorbidity. Medicare Part D generally does not cover anti-obesity medications, though the Treat and Reduce Obesity Act has been introduced in Congress to change this. Employer-sponsored self-funded plans are increasingly adding coverage. Check with your insurer and be prepared to appeal if initially denied.
Yes. In December 2022, the FDA approved Wegovy for adolescents aged 12 and older with obesity (BMI at the 95th percentile or greater for age and sex). The STEP TEENS trial showed a 16.1% reduction in BMI vs placebo over 68 weeks. The dosing schedule for adolescents is the same as for adults.
Wegovy experienced significant supply constraints starting shortly after its 2021 launch due to overwhelming demand. Novo Nordisk had difficulty scaling manufacturing capacity quickly enough. Lower initiation doses (0.25 mg and 0.5 mg) were periodically unavailable, making it difficult for new patients to start treatment. Supply has gradually improved through 2024-2025 as Novo Nordisk invested in expanded manufacturing facilities, but intermittent shortages at specific dose levels may still occur.
Several options exist for reducing costs: the Novo Nordisk patient savings card (for commercially insured patients), patient assistance programs for uninsured individuals, appeal of insurance denials using clinical data, and discussion with your provider about alternative GLP-1 options that may have better coverage. Some compounding pharmacies offered compounded semaglutide during the shortage, though the FDA's stance on compounding has tightened as supply normalizes.